News No EMA deal would ‘disable’ UK pharma, says Bell Failure to strike a Brexit deal allowing alignment with the European Medicines Agency would be ‘catastrophic’ for the UK life sciences sector.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.